Tevogen Bio (TVGN) to Release Quarterly Earnings on Wednesday

Tevogen Bio (NASDAQ:TVGN) will likely be releasing its results before the market opens on Wednesday, April 1st. Analysts expect Tevogen Bio to post earnings of ($0.0620) per share for the quarter.

Tevogen Bio Stock Performance

Shares of NASDAQ:TVGN opened at $5.22 on Wednesday. Tevogen Bio has a 52-week low of $4.89 and a 52-week high of $75.50. The company has a market capitalization of $21.14 million, a PE ratio of -0.55 and a beta of -0.76. The company has a fifty day moving average of $12.23 and a 200-day moving average of $22.41.

Analysts Set New Price Targets

TVGN has been the topic of a number of research reports. D. Boral Capital lowered Tevogen Bio from a “buy” rating to a “hold” rating in a research report on Wednesday, March 4th. Wall Street Zen downgraded Tevogen Bio to a “strong sell” rating in a research report on Saturday. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Tevogen Bio in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Tevogen Bio presently has a consensus rating of “Reduce” and an average price target of $100.00.

Institutional Trading of Tevogen Bio

Several institutional investors have recently modified their holdings of TVGN. Bridgeway Capital Management LLC increased its holdings in Tevogen Bio by 66.7% in the third quarter. Bridgeway Capital Management LLC now owns 82,500 shares of the company’s stock valued at $65,000 after purchasing an additional 33,000 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Tevogen Bio by 126.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 273,694 shares of the company’s stock worth $91,000 after buying an additional 152,572 shares during the period. Finally, Deutsche Bank AG lifted its holdings in Tevogen Bio by 304.1% during the 4th quarter. Deutsche Bank AG now owns 173,734 shares of the company’s stock worth $57,000 after buying an additional 130,738 shares during the period.

Tevogen Bio Company Profile

Tevogen Bio plc (NASDAQ:TVGN) is a clinical-stage biotechnology company focused on developing personalized natural killer (NK) cell immunotherapies for oncology and severe viral diseases. Leveraging proprietary induced pluripotent stem cell (iPSC) and donor-derived NK cell platforms, Tevogen Bio aims to create off-the-shelf cell therapy products that offer scalable and cost-efficient treatment options. The company’s lead candidate, TVGN-484, is an allogeneic NK cell therapy in clinical trials for relapsed or refractory acute myeloid leukemia (AML).

In addition to its lead program in AML, Tevogen Bio’s pipeline includes preclinical NK cell candidates directed against hematological malignancies, solid tumors and viral infections.